Eagle Pharmaceuticals Newsroom

Eagle Pharmaceuticals TO Pay Curia $26.5M, With Payments Scheduled For $10M On July 5, 2024, Another $10M By February 17, 2025, And Final $6.5M By July 7, 2025; Filed Stipulation Of Discontinuance With Prejudice For NY Court Action

Eagle Pharmaceuticals TO Pay Curia $26.5M, With Payments Scheduled For $10M On July 5, 2024, Another $10M By February 17, 2025, And Final $6.5M By July 7, 2025; Filed Stipulation Of Discontinuance

BenzingaJul 10 20:11

Express News | Eagle Pharmaceuticals: To Pay Curia $26.5 Mln Under a Settlement Agreement

BreakingsJul 10 20:03

Express News | Nantahala Capital Management, LLC Reports 15.1% Passive Stake in Eagle Pharmaceuticals Inc as of June 30- SEC Filing

BreakingsJul 4 02:04

Express News | Shares of Eagle Pharmaceuticals Hit Session High of $5.13 in Volume Jump, Last up 9.9% at $5.00

BreakingsJun 27 03:27

Express News | Eagle Pharmaceuticals Inc Says on May 28, Co Requested Hearing Before Hearings Panel of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing

BreakingsMay 29 20:28

Eagle Pharmaceuticals Shares Are Trading Lower After the Company Announced a Nasdaq Listing Receipt.

Eagle Pharmaceuticals Shares Are Trading Lower After the Company Announced a Nasdaq Listing Receipt.

BenzingaMay 23 00:35

Express News | Eagle Pharmaceuticals Announces Receipt of Delisting Notification From Nasdaq

BreakingsMay 22 21:00

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.

MT NewswiresApr 16 03:59

Eagle Pharmaceuticals Says Phase 3 Data Show Amisulpride's Sustained Antiemetic Effect; Shares Rise

Eagle Pharmaceuticals (EGRX) shares climbed 9% in recent trading after the company said Monday that it will present phase III trial data showing that intravenous amisulpride may sustain an antiemetic

MT NewswiresApr 16 01:49

Eagle Pharmaceuticals To Present Additional Data From Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National Conference

Eagle Pharmaceuticals To Present Additional Data From Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National

BenzingaApr 15 19:25

323 drugs, hurry up! America is facing the biggest “drug shortage” in history...

The US now seems to be facing an unprecedented “drug shortage”...

cls.cnApr 15 14:37

HROW, HCAT and EGRX Are Among After Hour Movers

Seeking AlphaApr 13 05:05

Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays

TipRanksApr 13 04:34

Eagle Pharmaceuticals Announces Receipt Of Notification Of Deficiency From Nasdaq Regarding Requirement To Timely File Annual Report On Form 10-K

Eagle Pharmaceuticals Announces Receipt Of Notification Of Deficiency From Nasdaq Regarding Requirement To Timely File Annual Report On Form 10-K

BenzingaApr 13 04:09

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency From Nasdaq Regarding Requirement to Timely File Annual Report On Form 10-K

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency From Nasdaq Regarding Requirement to Timely File Annual Report On Form 10-K.

GlobeNewswireApr 13 04:05

Sector Update: Health Care

Health care stocks fell late Monday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both easing 0.1%, paring earlier losses. The iShares Biotechnology ETF (

MT NewswiresMar 12 03:28

Eagle Pharmaceuticals CFO Resigns; Shares Fall

Eagle Pharmaceuticals (EGRX) shares fell 6% in recent Monday trading after Brian Cahill resigned as chief financial officer on Friday, effective immediately. The company said in a regulatory filing th

MT NewswiresMar 12 02:05

Eagle Pharmaceuticals Announces CFO Transition and Leadership Changes

TipRanksMar 9 06:03

Eagle Pharmaceuticals Announces Workforce Reduction

InvestingMar 1 00:02

Eagle Pharmaceuticals Faces Nasdaq Delisting Deadline

TipRanksFeb 13 22:02